SCHEMBL21779263

SCHEMBL21779263

CC(C)(C)Nc1cccc2cc[nH]c12

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR3C1 P04150 1/20 0.60
▸ PGR P06401 1/20 0.60
▸ NR3C2 P08235 1/20 0.60
▸ AR P10275 1/20 0.60
▸ AHR P35869 1/20 0.46
▸ BCHE P06276 3/20 0.41
▸ KEAP1 Q14145 1/20 0.41
▸ PDPK1 O15530 1/20 0.40
▸ TRPV1 Q8NER1 1/20 0.39
▸ BACE1 P56817 1/20 0.38
▸ EGFR P00533 1/20 0.38
▸ REN P00797 1/20 0.36
▸ PTPN11 Q06124 1/20 0.36
▸ PRKCQ Q04759 1/20 0.36
▸ ACLY P53396 1/20 0.35
▸ BRD4 O60885 1/20 0.33
▸ TAF1 P21675 1/20 0.33
▸ BRPF1 P55201 1/20 0.33
▸ CREBBP Q92793 1/20 0.33
▸ CECR2 Q9BXF3 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13085560 0.79 NR3C1 (0.61) NR3C1PGRNR3C2ARAHR
SCHEMBL2161116 0.75 NR3C1 (1.00) NR3C1PGRNR3C2ARAHR
SCHEMBL22001247 0.74 NR3C1 (0.56) NR3C1PGRNR3C2ARAHR
SCHEMBL21481533 0.72 NR3C1 (0.52) NR3C1PGRNR3C2ARBCHE
SCHEMBL31456523 0.71 NR3C1 (0.57) NR3C1PGRNR3C2ARBCHE
SCHEMBL6091339 0.71 NR3C1 (0.57) NR3C1PGRNR3C2ARBCHE
SCHEMBL13884296 0.71 IDO1 (0.39) NR3C1PGRNR3C2ARKEAP1
SCHEMBL3793079 0.71 AHR (0.50) NR3C1PGRNR3C2ARAHR
SCHEMBL13994047 0.70 DHPS (0.52) AHRTRPV1EGFR
SCHEMBL19187519 0.70 NR3C1 (0.56) NR3C1PGRNR3C2ARAHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11919858-B2 Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases CALGENT BIOTECHNOLOGY CO., LTD. (TW) 2024-03-05 — — US disclosed
US-11833122-B2 Aminonaphthoquinone compounds for treatment and/or prevention of fibrosis diseases CALGENT BIOTECHNOLOGY CO., LTD. (TW) 2023-12-05 — — US disclosed
US-20200148643-A1 AMINONAPTHOQUINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITION FOR BLOCKING UBIQUITINATION-PROTEASOME SYSTEM IN DISEASES CALGENT BIOTECHNOLOGY CO., LTD. (TW) 2020-05-14 — — US disclosed
US-10577328-B2 Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases TAIPEI MEDICAL UNIVERSITY (TW) 2020-03-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200148643-A1 AMINONAPTHOQUINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITION FOR BLOCKING UBIQUITINATION-PROTEASOME SYSTEM IN DISEASES UBQLN1, UBQLN2, PSMB1 NR3C1 1942/4885PGR 3593/4885NR3C2 3042/4885
US-10577328-B2 Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases PSMB1, UBQLN1, PSMB5 NR3C1 2616/4885PGR 3950/4885NR3C2 3207/4885
US-11833122-B2 Aminonaphthoquinone compounds for treatment and/or prevention of fibrosis diseases KEAP1, GOT2, COL1A1 NR3C1 2355/4885PGR 4029/4885NR3C2 1808/4885
US-11919858-B2 Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases UBQLN1, PSMB1, UBQLN2 NR3C1 2097/4885PGR 2707/4885NR3C2 2125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback